Elonva

RSS

corifollitropin alfa

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Elonva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Elonva.

This EPAR was last updated on 18/01/2019

Authorisation details

Product details
Name
Elonva
Agency product number
EMEA/H/C/001106
Active substance
corifollitropin alfa
International non-proprietary name (INN) or common name
corifollitropin alfa
Therapeutic area (MeSH)
  • Reproductive Techniques, Assisted
  • Ovulation Induction
Anatomical therapeutic chemical (ATC) code
G03GA09
Publication details
Marketing-authorisation holder
Merck Sharp Dohme Limited
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
25/01/2010
Contact address
Hertford Road
EN11 9BU Hoddesdon
United Kingdom

Product information

28/09/2018 Elonva - EMEA/H/C/001106 - IG/0968

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Controlled ovarian stimulation in combination with a gonadotrophin-releasing-hormone antagonist for the development of multiple follicles in women participating in an assisted-reproductive-technology programme.

Assessment history

How useful was this page?

Add your rating